ConferencePoster
 (2024)

Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial

Saad, F; Vjaters, E; Shore, ND; Olmos, D; Xing, N; Gomes, A.J.P.D.S.; Mota, A.C.A.; Salman, P; Jievaltas, M; Ulys, A et al